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Abstract: Background: One of the most common etiology in the diagnosis of pancytopenia in physician practice is 
megaloblastic anemia. However there is significant confusion associated with marrow megaloblastic features, which 
need not always because of pancytopenia. They may be just co-incidental findings. Its often difficult to establish that the 
peripheral pancytopenia is related to marrow megaloblastic features, as Vitamin B12 and folate are often normal in these 
cases [because of prior treatment] 
Aim: This study was conducted to develop a probability predicting system for possible incidence and severity of 
pancytopenia as a result of megaloblastic anemia.  
Materials and Methods: This is a retrospective analysis conducted at a tertiary care center with approximately 2,000 new 
cases of megaloblastic anemia. We Hypothesized age, duration of symptoms, Mean Corpuscular Volume [MCV], 
nutritional status, B12 and folate levels, underlying illness and response to therapy as possible factors associated with 
pancytopenia of megaloblastic anemia. Receiver operating characteristic (ROC) curves were drawn to predict the cutoff 
values for risk factors, and a final scoring system was developed with sensitivity and specificity data. 
Results: A total of 458 patients with pancytopenia and marrow findings of megaloblastic anemia were analyzed. Based 
on ROC analysis, following cutoff values were selected: age > 40 years or <20, Folate <30% lower limit, B12 any value 
close to lower limit of reference laboratory value, Mean Corpuscular Volume>110 fl, duration of symptoms more than 18 
weeks, Serum Albumin <2.5 gm/dl [taken as marker for nutrition]. The remaining factors were indicated as present or 
absent. A score of 1 was assigned for the above factors if they were present. For patients, the final score of 2 or less 
there is 22% probability of having pancytopenia while patients having score of 6 or more have 89% probability. Similarly 
when the Mean Corpuscular Volume recovered/reduced by 8 fl at week 3, patients have positive predictable recovery 
pattern. Those who does not have such recovery by week 3, the etiology of pancytopenia is unlikely to be megaloblastic 
anemia. And they need further evaluation  
Conclusion: The current tool is fairly accurate in predicting development of pancytopenia in patients with low B12 and 
folate/megaloblastic anemia. This will further help clinicians to look for other reasons of pancytopenia in case, where 
MCV does not recover beyond week 3 of therapy, so that valuable time of patient is not lost in resource constraints 
nations like India.  
Keywords: Anemia, pancytopenia, Megaloblastic anemia, India, Vitamin B12. 
INTRODUCTION 
Pancytopenia is an important entity encountered in 
clinical practice. The clinical definition is the 
simultaneous presence of anemia, leucopenia and 
thrombocytopenia. Therefore it exists when 
Hemoglobin (Hb) is less then 13.5g/dl in males or 
11.5g/dl in females; the leucocytes count of less then 
4x103/l and the platelets count of less than 150x103/l. 
[1] There are varying trends in its clinical pattern, 
etiology, treatment and outcome. The severity and 
etiology of this clinico- pathological condition determine 
the management and prognosis of the patients. Among 
the top causes, megaloblastic anemia is considered 
commonest in major studies done from this 
subcontinent ranging from 24-76% of all etiologies. [1-
10] The Vitamin B12 and Folate deficiencies in their  
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mild form often may go undetected and it becomes 
apparent only during times of stress or increased 
demand. However once it is in its severest forms, the 
picture of megaloblastic anemia is varied and often 
confusing. The commonest dilemma for physician is - 
when to do a bone marrow in presence of 
megaloblastic peripheral picture?. As megaloblastic 
anemia responds readily with therapy, the question of 
postponement of doing a marrow is not scientifically 
answered yet. Here we proposed one model, which 
predicts that the probable cause of Pancytopenia is 
megaloblastic anemia based on few lab parameters 
and clinical characters. The model predicts both the 
risk for development of pancytopenia in cases of 
megaloblastic anemia as well.  
METHODS 
This is a retrospective analysis conducted at a 
tertiary care center with approximately 2,000 new 
cases of megaloblastic anemia. A total of 458 patients 
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with pancytopenia and marrow findings of 
megaloblastic anemia were analyzed. In view of this 
being retrospective analysis, no eligibility criteria was 
used and only those cases with complete clinical 
details were chosen for analysis. We Hypothesized 
age, duration of symptoms, Mean Corpuscular Volume, 
nutritional status, B12 and folate levels, underlying 
illness and response to therapy as possible factors 
associated with pancytopenia of megaloblastic anemia. 
Receiver operating characteristic (ROC) curves were 
drawn to predict the cutoff values for risk factors, and a 
final scoring system was developed with sensitivity and 
specificity data. Medical version 7.0 for Windows 
(MedCalc Software, Mariakerke, Belgium) was used for 
the analysis. Risk of age was assessed by 5-year 
interval for age, for B12 and folic acid at 10% lesser 
value from the highest value of the normal, MCV at 5 
Units interval, 0.5 gm/dL intervals for albumin levels, 
duration of symptoms at 2 weekly interval. For 
comorbid conditions, as present or absent and 
assigned a score of 1 and 0, respectively. For all the 
remaining parameters values above cutoff were scored 
as 1 and values below cutoff were scored as indicated 
by ROC curves. Sensitivity and specificity for the final 
score were assessed for each score level, and based 
on the percentage of patients experiencing 
pancytopenia; they were grouped into low-, 
intermediate-, and high-risk groups. 
A total of 458 patients with pancytopenia and 
marrow findings of megaloblastic anemia were 
analyzed. Based on ROC analysis, the following cutoff 
values were selected: age > 40 years or <20, Folate 
<30% lower limit, B12 any value close to lower limit of 
reference lab, MCV>110, duration of symptoms more 
than 18 weeks, Albumin value <2.5 (Figure 1). The 
remaining factors were indicated as present or absent. 
A score of 1 was assigned for the above risk factors. 
After the scoring system, the categories were chosen 
again by using the ROC curves and scores of 2 or less, 
and 6 or above predicted the differences in the 
incidence of pancytopenia with megaloblastic anemia. 
For patients, the final score of 2 or less there is 22% 
probability of having pancytopenia while patients 
having score of 6 or more have 89% probability. 
Similarly when the Mean Corpuscular Volume 
recovered/reduced by 8 fl at week 3, patients have 
positive predictable recovery pattern. Those who does 
not have such recovery by week 3, the etiology of 
pancytopenia is unlikely to be megaloblastic anemia. 
And they need further evaluation  
DISCUSSION 
The diagnosis of megaloblastic anemia in our study 
was established by characteristic peripheral picture, 
Vitamin B12 levels, folate levels as well as bone 
marrow findings. The high prevalence of nutritional 
anemia in India has been cited for the increased 
frequency of megaloblastic anemia. Because of 
geographical and social similarities, nutritional anemia 
may also be responsible for increased frequency of 
megaloblastic anemia, with Vitamin B12 deficiency 
being more prevalent than folate deficiency in people 
with vegetarianism.  
Since the closest differential diagnosis of this 
condition is aplastic anemia and both may have 
 
Figure 1: ROC curve for the hypothesize risk factors Results. 
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presence of macrocytes in peripheral smear 
examination, it pose a difficulty in distinction between 
the two in the absence of macro-ovalocytes and hyper 
segmented neutrophils [11, 12]. Evidence in previous 
studies suggests that myeloperoxidase index 
measurement may assist differentiation of 
megaloblastic from aplastic anemia [13] 
The etiology and pathogenesis of this 
heterogeneous group of disorders under “megaloblastic 
anemia”share common characteristics: like  
• Large cells with an arrest in nuclear maturation. 
• Nuclear maturation is immature relative to 
cytoplasmic maturity. 
• Hence, these cells that can be seen in bone 
marrow aspirates and in peripheral smears have 
been called megaloblasts. 
These abnormalities are due to impaired DNA 
synthesis and, to a lesser extent, RNA and protein 
synthesis. Expectedly, these changes are most 
apparent in rapidly dividing cells such as blood cells 
and gastrointestinal cells. However, these are not 
limited to the above and WBC series like 
hypersegmented neutrophils can be seen on peripheral 
smears and giant bands occur in bone marrow with 
platelet morphological alterations. The clinical course 
could be acute or chronic and can have varied 
spectrum of severe anemia, pancytopenia, 
gastrointestinal dysfunction, gloss it is, personality 
changes, psychosis, and neurological disorders. [14-
16] 
In the present study patients had a mean age of 34 
years and majority were females, which is in 
agreement with the national trends, where most of the 
cases are diagnosed in the middle age. The relatively 
lower incidence of comorbid conditions is due to age 
distribution (only 20% [44 patients] of the study 
population is above 45 years, which is the median age 
for development of diabetes in Indian population). 
Although literature suggest elevated levels of lactate 
dehydrogenase (LDH) and indirect bilirubin should fall 
rapidly [within 2 weeks] and a prolonged elevation of 
the LDH level indicates a failure of therapy, 
development of iron deficiency, or an error in diagnosis, 
the present study suggest that Indians may take longer 
time for recovery [3-4 weeks] and physicians should 
wait for the same. Reticulocytosis should be evident 
within 3-5 days and peaks in 4-10 days. Leukocyte and 
platelets counts are usually restored to normal within 
days after therapy has been started, but 
hypersegmented neutrophils may persist for 10-14 
days, which again are bit delayed in the studies 
population. The hemoglobin should rise approximately 
1 g/dL each week. This rise is valuable for monitoring a 
complete response. If the hemoglobin does not rise 
appropriately and is not normal within 2 months, other 
causes of anemia, such as iron deficiency, should be 
considered. Overall for patients, the final score of 2 or 
less there is 22% probability of having pancytopenia 
while patients having score of 6 or more have 89% 
probability. Similarly when the Mean Corpuscular 
Volume recovered/reduced by 8 fl at week 3, patients 
have positive predictable recovery pattern. Those who 
does not have such recovery by week 3, the etiology of 
pancytopenia is unlikely to be megaloblastic anemia. 
And they need further evaluation  
CONCLUSION 
The current tool is fairly accurate in predicting 
development of pancytopenia in patients with low B12 
and folate/megaloblastic anemia. This will further help 
clinicians to look for other reasons of pancytopenia in 
case MCV doesn't recover on week 3, so that valuable 
time of patient is not lost in resource constraints 
nations like India.  
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